Our results indicated a broad prevalence of pain problem in PD patients (58.6%), beginning early stages (50% for the Ist phase). The most stable pain associations were found utilizing the PD stage, levodopa doses, extent of engine symptoms (postural problems and hypokinesia manifestations) and motor complications («off-periods» and dyskinesias), along with non-motor PD manifestations despair and autonomic dysfunctions (constipation, swallowing conditions, and regular urination). The regression evaluation revealed, that the seriousness of engine complications and depression were the predictors of discomfort occurrence. The pain sensation problem in customers with PD of I-III stages underwent significant regression (by 51% and 62%, after 1.5 and half a year of treatment, respectively) after ADR (piribedil) inclusion with their treatment; it really is probably because of enhancing the engine component and decreasing despression symptoms. The piribedil inclusion adds into the reduced total of discomfort syndrome, irrespective will it be used in monotherapy or perhaps in conjunction with levodopa arrangements.The piribedil inclusion contributes to the reduction of pain syndrome, irrespective will it be utilized in monotherapy or in combination with levodopa preparations. To examine clinico-psychological profile and life quality of clients with post-COVID problem. We examined 162 customers elderly Gut microbiome 24-60 many years with confirmed SARS-CoV-2 infection which having signs that served since the foundation for the diagnosis of post-COVID problem. Customers underwent general neurologic and somatic assessment with allocation for the corresponding neurological syndromes. The strength and quality of pain had been evaluated making use of the McGill Pain survey. The level of psychosocial stress had been dependant on the Holmes-Ray survey, the recognition and extent of asthenia – by the MFI-20 asthenia scale. The degree of reactive and private anxiety had been studied according to the Spielberger-Khanin survey, depression – in accordance with the Beck scale. The evaluation of life high quality was performed utilising the Russian variation of SF-36 questionnaire. To correct the identified disorders, Mexidol ended up being utilized in accordance with the plan 500 mg once daily intravenously for two weeks, followed by Mexidol FORTE 250 750 mg a day orally (250 mg 3 times each and every day) for just two months. This course of therapy with Mexidol in clients with post-COVID problem led to reduce into the extent of subjective and objective symptoms, asthenic, anxiety and depressive disorder, and enhanced the life high quality of clients. The high efficacy and protection of sequential treatment with Mexidol (treatments accompanied by Lysipressin mw tablets of Mexidol FORTE 250) has been shown.The high efficacy and safety of sequential therapy with Mexidol (injections followed closely by tablets of Mexidol FORTE 250) has been shown. The research included 56 patients (10 males and 46 females), aged 18 to 50 many years, with vestibular migraine and a control group (patients with migraine without au-ra). The analysis of neurologic status, features of the psychoemotional sphere, accentuations of personality and temperament associated with individual, standard of living had been completed. The Beck Depres-sion stock, the Spielberger-Khanin State-Trait Anxiety stock test, the K. Leonhard – H. Schmischek Inventory ensure that you the Vestibular Rehabilitation Benefit Questionnaire had been admin-istered. The following functions between two groups were uncovered lack of considerable differences in characteristic anxiety, statistically significant variations in state anxiety and the extent of depressive signs, in addition to considerable variations within the spectral range of character accentuations and a lack of total well being. The outcomes tend to be appropriate and important in the field of handling of customers with vestibular migraine and allow us to focus due interest on psychoemotional distinctiveness and lack of well being in this debilitating pathology, for the probability of providing the nec-essary individual technique to get over the condition.The outcomes tend to be appropriate and important in the world of management of patients with vestibular migraine and allow us to concentrate due attention on psychoemotional distinctiveness and not enough lifestyle in this devastating pathology, when it comes to possibility for presenting the nec-essary individual technique to overcome the disease. To obtain the ideal Translational Research healing dosage regarding the anti-B cell mAb divozilimab (DIV) in line with the efficacy and security data of intravenous administration at a dose of 125 mg or 500 mg in customers with relapsing remitting several sclerosis (RRMS) in comparison to placebo (PBO) and teriflunomide (TRF). To review the efficacy and protection of DIV within 24 months of therapy. A multicenter, randomized, double-blind and double-masked, placebo-controlled period 2 medical test (CT) BCD-132-2 involved 271 adult clients with RRMS from 25 centres In Russia. Clients were randomly assigned (2221) into 4 groups TRF, DIV 125 mg, DIV 500 mg and PBO. After screening patients entered towards the primary duration, which contained one period of treatment for 24 weeks. The primary endpoint had been the total number of gadolinium-enhancing T1 lesions (Gd+) observed on brain MRI scans after 24 weeks (per scan – involves calculating the mean value of the score from all of the MRI assessments performed for each participant within the research).